Related Experiment Video
Updated: Aug 20, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro
Hesam Farivar-Mohseni1, Stanley J Kandzari, Stanley Zaslau
1Department of Surgery, Robert C. Byrd Health Science Center, West Virginia University, PO Box 9238, Morgantown, WV 26506-9238, USA.
Background:
We hypothesized that combined treatment with cyclooxygenase (Cox)-1 (catechin) and Cox-2 (NS398)-specific inhibitors would reduce cellular proliferation synergistically in genitourinary cancer.
Methods:
Bladder (T24 and TCCSUP) and prostate (DU145, LnCaP, and PC3) cancer cell lines were treated with catechin and NS398 at a dose of 100 mumol/L as single and combined treatments. Viability was measured by MTT assay at 24 and 72 hours.
Results:
Significant synergism of Cox-1 and Cox-2 inhibitors was observed in both bladder cancer lines at both 24 and 72 hours. Synergism of Cox-1 and -2 inhibitors also was noted in the DU145 cells at 72 hours, LnCap cells at 24 hours, and PC3 at both 24 and 72 hours.
Conclusions:
Significant synergistic effects exhibited by the combination of Cox-1 and Cox-2 inhibitors suggest that these could become a highly effective treatment modality for carcinoma of both the bladder and prostate.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Inhibition of Cdk Activity